November 15, 2024 10:35 AM ESTUpdated November 19, 04:20 PM
News Briefing

Vi­tal­li ends work on Dae­woong as­set; Alec­tor’s $50M loan

ENDPOINTS

Plus, news about Bavar­i­an Nordic, Nu­vec­tis Phar­ma, Flash­point Ther­a­peu­tics, Spar­i­an Bio­sciences and TFF Phar­ma­ceu­ti­cals:

Vi­tal­li Bio ax­es Dae­woong as­set: Vi­tal­li, found­ed by Joe Jimenez’s …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

As­traZeneca is de­nied full FDA ap­proval of An­dexxa fol­low­ing crit­i­cal ad­vi­so­ry meet­ing

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

A service from the Financial Times